Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

LXEO

Lexeo Therapeutics Inc.

May 02 • 11:43AM ET

12.33

Dollar change +0.03
Percentage change 0.24	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWO IWC VTWG VTWV RYLD

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.49	Insider Own	39.82%	Shs Outstand	26.65M	Perf Week	1.40%
Market Cap	328.59M	Forward P/E	-	EPS next Y	-3.41	Insider Trans	11.99%	Shs Float	16.04M	Perf Month	-12.86%
Income	-66.39M	PEG	-	EPS next Q	-0.74	Inst Own	48.23%	Short Float	5.21%	Perf Quarter	-26.65%
Sales	0.00M	P/S	-	EPS this Y	74.03%	Inst Trans	-	Short Ratio	7.47	Perf Half Y	-
Book/sh	4.26	P/B	2.89	EPS next Y	-5.78%	ROA	-	Short Interest	0.84M	Perf Year	-
Cash/sh	4.56	P/C	2.71	EPS next 5Y	-	ROE	-	52W Range	9.00 - 22.33	Perf YTD	-8.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-54.17%	52W High	-44.78%	Beta	-
Dividend TTM	-	Quick Ratio	7.21	Sales past 5Y	19.69%	Gross Margin	-	52W Low	37.00%	ATR (14)	0.91
Dividend Ex-Date	-	Current Ratio	7.21	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	42.46	Volatility	6.28% 7.51%
Employees	58	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.40
Option/Short	No / Yes	LT Debt/Eq	0.08	EPS Q/Q	6.30%	Payout	-	Rel Volume	1.53	Prev Close	12.30
Sales Surprise	-	EPS Surprise	-23.44%	Sales Q/Q	-100.00%	Earnings	Mar 11 BMO	Avg Volume	111.97K	Price	12.33
SMA20	-1.44%	SMA50	-12.53%	SMA200	-12.50%	Trades		Volume	63,893	Change	0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-28-23	Initiated	Stifel	Buy	$20
Nov-28-23	Initiated	RBC Capital Mkts	Outperform	$22
Nov-28-23	Initiated	Leerink Partners	Outperform	$19
Nov-28-23	Initiated	JP Morgan	Overweight	$20
Nov-28-23	Initiated	Chardan Capital Markets	Buy	$23

Apr-22-24 07:30AM	Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +5.06%
Apr-16-24 07:30AM	Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy (GlobeNewswire)
Mar-13-24 04:22PM	Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing (GlobeNewswire) +5.67%
Mar-11-24 07:42AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
07:30AM	Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing (GlobeNewswire)
07:00AM	Loading…
Feb-05-24 07:00AM	Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments (GlobeNewswire)
Jan-03-24 07:00AM	Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 07:00AM	Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (GlobeNewswire) +8.71%
Dec-13-23 04:59AM	Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs (GuruFocus.com)
Dec-11-23 12:05PM	LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023 (InvestorPlace) -12.94%
07:00AM	Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Nov-30-23 08:42AM	J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential (TipRanks)
Nov-02-23 09:51PM	Lexeo Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Longitude Capital Partners IV,	10% Owner	Nov 07 '23	Buy	11.00	454,545	4,999,995	2,567,100	Nov 09 08:32 PM
Omega Fund VI, L.P.	10% Owner	Nov 07 '23	Buy	11.00	454,545	4,999,995	2,157,623	Nov 09 08:36 PM
Lundbeckfond Invest A/S	10% Owner	Nov 07 '23	Buy	11.00	227,272	2,499,992	1,835,959	Nov 09 08:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXEO

Lexeo Therapeutics Inc.

Upgrade your FINVIZ experience